JP2022535694A5 - - Google Patents

Info

Publication number
JP2022535694A5
JP2022535694A5 JP2021569057A JP2021569057A JP2022535694A5 JP 2022535694 A5 JP2022535694 A5 JP 2022535694A5 JP 2021569057 A JP2021569057 A JP 2021569057A JP 2021569057 A JP2021569057 A JP 2021569057A JP 2022535694 A5 JP2022535694 A5 JP 2022535694A5
Authority
JP
Japan
Prior art keywords
extended
release composition
manufactured article
use according
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021569057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535694A (ja
JP7664855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/054984 external-priority patent/WO2020240417A1/en
Publication of JP2022535694A publication Critical patent/JP2022535694A/ja
Publication of JP2022535694A5 publication Critical patent/JP2022535694A5/ja
Application granted granted Critical
Publication of JP7664855B2 publication Critical patent/JP7664855B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569057A 2019-05-27 2020-05-26 乳がんを処置するためのリュープロリド酢酸塩組成物およびその使用方法 Active JP7664855B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27
US62/853,153 2019-05-27
PCT/IB2020/054984 WO2020240417A1 (en) 2019-05-27 2020-05-26 Leuprolide acetate compositions and methods of using the same to treat breast cancer

Publications (3)

Publication Number Publication Date
JP2022535694A JP2022535694A (ja) 2022-08-10
JP2022535694A5 true JP2022535694A5 (cg-RX-API-DMAC7.html) 2023-06-05
JP7664855B2 JP7664855B2 (ja) 2025-04-18

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569057A Active JP7664855B2 (ja) 2019-05-27 2020-05-26 乳がんを処置するためのリュープロリド酢酸塩組成物およびその使用方法

Country Status (17)

Country Link
US (2) US12453754B2 (cg-RX-API-DMAC7.html)
EP (1) EP3975990A1 (cg-RX-API-DMAC7.html)
JP (1) JP7664855B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220041782A (cg-RX-API-DMAC7.html)
CN (1) CN114144169A (cg-RX-API-DMAC7.html)
AR (1) AR119021A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020284587B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023904A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141456A1 (cg-RX-API-DMAC7.html)
EA (1) EA202193257A1 (cg-RX-API-DMAC7.html)
IL (1) IL288503A (cg-RX-API-DMAC7.html)
MX (1) MX2021014540A (cg-RX-API-DMAC7.html)
PH (1) PH12021552976A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112888RA (cg-RX-API-DMAC7.html)
TW (1) TWI757753B (cg-RX-API-DMAC7.html)
UY (1) UY38717A (cg-RX-API-DMAC7.html)
WO (1) WO2020240417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112888RA (en) 2019-05-27 2021-12-30 Tolmar International Ltd Leuprolide acetate compositions and methods of using the same to treat breast cancer
KR102742097B1 (ko) 2020-12-23 2024-12-11 톨마 인터내셔날 리미티드 혼합 주사기 밸브 어셈블리를 위한 시스템 및 방법
CN115518144A (zh) * 2021-06-26 2022-12-27 王婧宜 一种含有亮丙瑞林或其衍生物的口服药物组合物
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2637569C (en) * 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
EP3202814B1 (en) * 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
DE202009010095U1 (de) 2009-07-24 2009-10-22 Chang, Ti-Li, Houli Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
SG11202112888RA (en) 2019-05-27 2021-12-30 Tolmar International Ltd Leuprolide acetate compositions and methods of using the same to treat breast cancer
KR102162217B1 (ko) 2020-05-07 2020-10-06 주식회사 파인비엠 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트
KR102742097B1 (ko) 2020-12-23 2024-12-11 톨마 인터내셔날 리미티드 혼합 주사기 밸브 어셈블리를 위한 시스템 및 방법
AU2022331238A1 (en) 2021-08-19 2024-02-01 Carefusion 303, Inc. Pivc-integrated hemolysis-reduction accessories with anti-spillage component for direct blood draw
FR3131618A1 (fr) 2021-12-30 2023-07-07 Parker Hannifin Emea Sarl Dispositif de raccordement aseptique d’un tube

Similar Documents

Publication Publication Date Title
US20220354956A1 (en) Biodegradable drug delivery for hydrophobic compositions
AU2005251462B2 (en) Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons
CN103491946B (zh) 可生物降解的药物释放组合物
EP1250138B2 (en) Fulvestrant formulation
CN102933201B (zh) 抗真菌药物组合物
US20090325879A1 (en) Controlled release copolymer formulation with improved release kinetics
CN110201243A (zh) 一种复合药物涂层球囊导管及其制备方法
CA2716576A1 (en) Fulvestrant formulations
KR102915096B1 (ko) 연장 방출형 조성물을 이용한 중추성 성조숙증 어린이의 치료 방법
JP2022535694A (ja) 乳がんを処置するためのリュープロリド酢酸塩組成物およびその使用方法
EP3821920A1 (en) Combination for endoscopic surgery
JP2024501166A (ja) フルベストラントの徐放性医薬組成物及びその製造方法
CN116056687B (zh) 含有mtor抑制剂的外用制剂
JP2023538265A (ja) ホスホイノシチド3-キナーゼ阻害剤の製剤
CN101229150A (zh) 含紫杉烷的温控缓释注射剂及其制备方法
JP2024511353A5 (cg-RX-API-DMAC7.html)
KR20230094172A (ko) 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
WO2003080181A2 (en) Storage stable eplerenone formulation
WO2024194781A1 (en) Improved compositions
KR20240105964A (ko) 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법
KR20140147336A (ko) 도세탁셀을 함유하는 액상 주사용 조성물
EP4422636A1 (en) Inectable pharmaceutical composition for treatment of breast cancer
KR20230079071A (ko) 테스토스테론의 연장 전달을 위한 생분해성 폴리머 전달 시스템
HK1150021B (en) Fulvestrant formulation